Compagnie Lombard Odier SCmA lessened its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 59.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,163 shares of the conglomerate’s stock after selling 3,158 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Danaher were worth $497,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the company. Root Financial Partners LLC bought a new stake in shares of Danaher during the fourth quarter worth approximately $343,000. Figure 8 Investment Strategies LLC bought a new stake in shares of Danaher in the fourth quarter valued at approximately $2,102,000. Vontobel Holding Ltd. boosted its stake in shares of Danaher by 1.2% in the fourth quarter. Vontobel Holding Ltd. now owns 172,231 shares of the conglomerate’s stock valued at $39,536,000 after buying an additional 2,094 shares during the period. Bogart Wealth LLC boosted its stake in shares of Danaher by 11.2% in the fourth quarter. Bogart Wealth LLC now owns 37,548 shares of the conglomerate’s stock valued at $8,619,000 after buying an additional 3,783 shares during the period. Finally, York GP Ltd. bought a new stake in shares of Danaher in the fourth quarter valued at approximately $4,591,000. Institutional investors own 79.05% of the company’s stock.
Danaher Stock Up 1.5 %
Shares of NYSE:DHR opened at $206.66 on Friday. The company has a fifty day moving average of $230.00 and a 200-day moving average of $249.96. The company has a market capitalization of $149.26 billion, a PE ratio of 39.14, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70.
Danaher Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a $0.27 dividend. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.52%. Danaher’s payout ratio is 20.45%.
Analyst Upgrades and Downgrades
DHR has been the subject of several recent research reports. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Robert W. Baird cut their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Raymond James reiterated a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Wells Fargo & Company cut their price target on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, UBS Group lowered their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $278.00.
Get Our Latest Stock Report on DHR
Insider Activity at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by company insiders.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- There Are Different Types of Stock To Invest In
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- What is the Australian Securities Exchange (ASX)
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.